Search Results for “EC” – Page 193 – media

Dental equipment leader, completes important acquisition

Dental equipment pioneer Henry Schein announced that it has completed the acquisition of Shield Healthcare Inc. Shield Healthcare Inc. is a device company that directly provides home care medical products to patients. Henry Schein announced this transaction last year. 01 Enters the field of household appliances In August 2023, Henry Schein announced that he had signed an agreement to acquire a majority stake in Shield Healthcare, Inc. On the basis of Henry Schein’s acquisition of Prism Medical Products LLC in 2021, Shield Healthcare will expand Henry Schein’s existing medical business by providing diversified product series, including incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes products. In addition, it will provide patients with continuous blood glucose monitoring devices directly at home. As the healthcare industry continues to shift towards home care, we have expanded our business of directly providing medical products to patients through our partnership with Shield Healthcare, ...
- Source: drugdu
- 64
- September 24, 2024
Edward Life Sciences launches global business layoffs

After Edward Life Sciences (hereinafter referred to as Edward) sold its intensive care business to Becton DickinsonMedical for $4.2 billion, a major global layoff has begun. Approximately 3% of employees will be affected by this layoff, and according to proportional calculations, about 540 employees will be laid off. Edward CEO Bernard Zovighian stated that employees affected by the global layoffs have received notice today that some employees may temporarily stay to assist with the transformation of the intensive care business, while others may find other jobs within the company. 30.4 billion yuan sale, 4500 employees join Becton Dickinson Edward is deeply engaged in the fields of global structural heart disease, intensive care, and surgical monitoring. Currently, he has multiple advanced products such as heart valves, cardiac intervention therapy equipment, cardiac monitoring equipment, and surgical tools. Among them, with the “world’s first successfully implanted artificial mitral valve”, Edward firmly occupies the ...
- Source: drugdu
- 66
- September 24, 2024
Lilly expanded its autoimmune disease product layout

As one of the blue oceans in the field of autoimmune diseases , inflammatory bowel disease (IBD) treatment drugs are sought after and deployed by many multinational pharmaceutical companies. Recently, Eli Lilly acquired Morphic for US$3.2 billion and obtained its core pipeline α4β7 integrin inhibitor MORF-057, further expanding its influence in the field of gastrointestinal diseases. In addition to Eli Lilly, pharmaceutical giants including AbbVie, AstraZeneca, and Merck have laid out IBD treatment drugs and carried out related mergers and acquisitions. Behind the frequent actions, why do multinational pharmaceutical companies favor IBD treatment drugs so much? The dilemma of traditional treatment IBD is a chronic inflammatory bowel disease that mainly affects the digestive system. Its symptoms include severe diarrhea, frequent abdominal pain, blood in the stool, weight loss, and severe cancer. IBD mainly includes two types: ulcerative colitis (UC) and Crohn’s disease (CD). The two IBDs have both overlaps and ...
- Source: drugdu
- 68
- September 24, 2024
Domestic endoscopy giant acquires European counterparts

On September 18, Micro-Tech (NL) International B.V. announced that the company intends to use its own funds of no more than 36.72 million euros (equivalent to approximately 289 million yuan) to purchase 51% of the shares of Creo Medical S.L.U. (hereinafter referred to as “CME”) held by CreoMedical Group plc (hereinafter referred to as “Creo”) through its wholly-owned subsidiary Micro-Tech (NL) International B.V. After the completion of this transaction, CME will become a holding subsidiary of the company. The announcement shows that Creo is a medical device company headquartered in the UK and listed on the London Stock Exchange (stock code: CREO). Creo focuses on the development and commercialization of minimally invasive surgical equipment in the field of surgical endoscopy. Its main product is CROMA, an electrosurgical platform that can provide microwaves and bipolar radiofrequency for local cutting through a single accessory port, providing doctors with simplified and controllable surgical ...
- Source: drugdu
- 67
- September 24, 2024
The chairman of Sinopharm Holdings has been replaced, and he comes from China Resources Group

Recently, Sinopharm Holdings issued an announcement on changes in the composition of the board committee, and Zhao Bingxiang was appointed as a non-executive director of Sinopharm. According to the process at the end of August, “the board of directors of Sinopharm has decided to elect Zhao Bingxiang as chairman of the board of directors. This appointment must be approved by shareholders at the shareholders’ meeting before the appointment of its non-executive director can take effect.” Zhao Bingxiang’s appointment as a non-executive director of Sinopharm also means that His appointment as chairman of the state-controlled company takes effect. At present, Sinopharm’s official website and announcement information have been updated, and Zhao Bingxiang serves as the chairman, non-executive director and party committee secretary of Sinopharm Holdings. It is reported that Zhao Bingxiang has worked in the China Resources department for a long time. He has served as a senior researcher at the ...
- Source: drugdu
- 60
- September 24, 2024
Pharma Pro&Pack

Organiser：Indian IPMMA Association, GPE Exhibition Company Time：September 26 – 28, 2024 Address：HITEX Exhibition Centre, Izzat Nagar, Hyderabad 500 032, A.P. Exhibition hall：Hyderabad International Convention Center Product range: Pharmaceutical Processing Machinery: Tablets, capsules, liquids, injections, ointments, dry syrups, etc.; Pharmaceutical packaging machinery, packaging materials, and consumables; Environmental control, cleanroom technology, furniture, and services; Products and Services: Steam generators, heat exchangers, boilers, filters (air, water, floor), BMS (Building Management Systems), pumps, electrical appliances, etc.; About Pharma Pro&Pack： The Indian Pharmaceutical Machinery & Packaging Exhibition (Pharma Pro&Pack), abbreviated as the Indian Pharma Machinery Show, is held annually and is India’s professional exhibition for pharmaceutical machinery and packaging. The previous edition was held at the Hyderabad International Convention Center. With an exhibition area of 12,500 square meters, it featured 310 exhibitors and attracted 14,000 visitors. Organized by the Indian IPMMA Association and GPE Exhibition Company, Pharma Pro&Pack is the most influential, largest, ...
- Source: drugdu
- 169
- September 24, 2024
Yingsi Intelligent’s world’s first TNIK inhibitor ISM001-055 has achieved positive results in phase IIa clinical trials

·ISM001-055 is an innovative drug driven by generative artificial intelligence and fully developed independently by Insilicon Intelligence. It targets TNIK (Traf2/NCK interacting kinase) and has completed phase IIa clinical trials for the treatment of patients with idiopathic pulmonary fibrosis (IPF); ·This study lasted for 12 weeks, and its preliminary results showed that ISM001-055 exhibited good safety in IPF patients and showed a dose-dependent pharmacological trend in improving lung function indicators in patients; ·The positive clinical trial results of ISM001-055 also provide the first conceptual validation for AI driven drug development. Hong Kong, China, September 18, 2024- Yingsi Intelligent, a clinical stage biotechnology company driven by generative artificial intelligence (AI), announced that its pipeline ISM001-055 has achieved positive preliminary research results in a phase IIa clinical trial. ISM001-055 is a “first in class” small molecule inhibitor driven by generative AI for drug discovery and design, targeting TNIK (Traf2/NCK interacting kinase) for ...
- Source: drugdu
- 68
- September 23, 2024
Breaking the domestic gap! New Pulse Medical opens a new era in the TAVR market

Domestic companies have created a new situation in the TAVR market and created a new market engine. On August 14, 2024, the State Food and Drug Administration officially approved the domestic Prizvalve transcatheter aortic valve system developed by New Pulse Medical. As the first self-developed balloon-expandable valve launched in China, the Prizvalve valve system is expected to be the first to break the import monopoly, effectively improve the quality of life, and quickly capture market share. Aortic valve disease mainly includes aortic valve stenosis and aortic valve regurgitation. With the deepening of aging, the prevalence of cardiovascular diseases (including aortic valve stenosis) continues to rise, and the number of patients with aortic valve disease in the world and China has increased year by year. This change has not only had a serious impact on the quality of life of patients, but also posed severe challenges to the medical system. Traditional ...
- Source: drugdu
- 56
- September 23, 2024
豪掷84亿!全球心血管巨头又一收购

9月17日，波士顿科学宣布，已完成对Silk Road Medical（Nasdaq: SILK）的收购，总价约11.8亿美元（约合84亿人民币）。本次收购价格为每股27.50美元的现金价格，此次收购旨在扩大其在血管医疗领域的产品和服务。值得注意的是，这是波士顿科学在今年以来的第二笔“十亿美元级收购”。溢价38%，创新技术博得巨头青睐 Silk Road Medical是一家位于美国加州的创新医疗器械公司，专注于降低中风风险及其破坏性影响。该公司开创了一种治疗颈动脉疾病的新方法，称为经颈动脉血运重建术（TCAR），这也是能获得波士顿科学青睐、不惜溢价38%也要豪掷84亿囊获该公司的原因。据了解，TCAR是一种经过临床验证的手术，将神经保护的外科原理与微创血管内技术相结合，用于治疗有引起中风风险的颈动脉阻塞。TCAR对于颈动脉阻塞的治疗具有十分重要的意义，在Silk Road Medical开发TCAR之前，颈动脉病变患者只有两种选择：“颈动脉内膜剥脱术（CEA）”或者“经股颈动脉支架植入术”（TFCAS）。尽管这两种治疗方式能够治疗部分患者，但是这两种方式会带来很多并发症（例如脑梗塞）。根据海外公布的一项针对美国近40万例颈动脉血管重建患者的研究显示：与内膜剥脱术相比，TCAR术后的脑梗塞和心肌梗塞发生率较低；与支架植入术相比，TCAR术后的脑梗塞和死亡率均较低。通过大规模临床研究显示出TCAR更具安全性，这也再次映证了TCAR对于颈动脉阻塞治疗的重大突破。回归TCAR的技术本身，Silk Road Medical开创的TCAR技术主要包含两款核心产品：ENROUTE Transcarotid Neuroprotection System（ENROUTE 经颈动脉逆流血栓保护装置）和ENROUTE Transcarotid Stent System（ENROUTE® 经颈动脉支架系统）。  ENROUTE 经颈动脉逆流血栓保护装置 ENROUTE 经颈动脉逆流血栓保护装置是在穿过病灶之前实现大脑的血流逆转，在血管成形术和支架置入术期间提供栓塞保护。与传统依赖于远端放置的过滤器来捕获血栓的方式不同的是，该装置是通过血液逆流方法实现整个手术期间的栓塞保护，通过流量控制器中的过滤器收集小碎片和大碎片，过滤后的血液通过股静脉中的护套返回，从而实现类似 CEA 的神经保护。ENROUTE 经颈动脉逆流血栓保护装置是整个TCAR手术核心技术，也是区别于TFCAS手术的关键所在。  ENROUTE® 经颈动脉支架系统 ENROUTE® 经颈动脉支架系统是专为TCAR手术而设计的，能够自动符合解剖结构，并提供长期斑块稳定性，以预防未来中风。该系统特点包括：特定输送长度：57mm输送系统，符合人体工程学且精确的支架输送；优化的单元设计：提供所有开放式单元支架设计的最大覆盖范围，甚至能够自动适应最困难的解剖结构。 “买买买”策略，心血管业务持续增长在前文中也提到了，此次对Silk Road Medical的收购是波士顿科学在今年以来的第二笔“十亿美元级收购”，此前的第一笔为1月8日，波士顿科学以每股71美元的价格，总共37亿美元（约262亿人民币）的现金，收购治疗泌尿和肠道功能障碍的设备制造商Axonics。此外，在本月之中，波士顿科学还从贝朗医疗手中收购买两款吻合口漏解决方案产品——Eso-SPONGE（用于治疗上消化道吻合口漏和穿孔的产品）和Endo-SPONGE（用于治疗结直肠吻合口漏）。多年以来，波士顿一直坚持着并购策略，乐此不疲地“买买买”，长期发展之下，波士顿科学已成为医械行业的佼佼者。此前，波士顿科学所公布的2024年Q2季度业绩中，波士顿科学的营收与板块业务增长的趋势也十分喜人。 2024年Q2，波士顿科学营收42.1亿美元，净销售额实际增长14.5%，其中心血管业务占据64%，医疗手术业务占36%。分类别来看，心血管业务里当属电生理板块增长最为迅猛，全球净销售额增长121.9%，运营/有机增长124.6%。此板块的增长也得益于其7月8日在华获批上市的FARAPULSE™系列脉冲电场消融产品，该产品先在美国获批，一时间销售额暴增，并且欧洲大陆销售额也在持续增长。此次收购Silk Road Medical、囊获TCAR技术，对于波士顿科学的心血管业务来说更是再添一员潜力大将，业务板块也伴随着波士顿科学的多笔重磅收购而愈加丰富。来源：https://news.yaozh.com/archive/44239.html
- Source: drugdu
- 53
- September 21, 2024
Can Increased Investment in Cell Therapy Drive CAR-T Product Growth?

Recently, Fosun Pharma (stock code: 600196.SH; 02196.HK) announced that its subsidiary, Fosun Pharma Industry, plans to invest $27 million in cash to acquire 50% of the equity of Fosun Kite held by Kite Pharma. Once this equity transfer is completed, Fosun Pharma will wholly own Fosun Kite and plans to invest an additional $10 million or its equivalent in renminbi as a capital increase for Fosun Kite. On the same day the equity transfer agreement was signed, Fosun Kite and Kite Pharma comprehensively revised and restated their original licensing agreement, signing a “Revised and Restated Licensing Agreement.” According to this agreement, Fosun Kite has obtained exclusive rights to develop, produce, and commercialize Yescarta® and Brexu-Cel (Fosun Kite’s research project FKC889) in mainland China, Hong Kong, and Macau, and within the field of cancer treatment. Additionally, Fosun Kite plans to change its name to Fosun Kairui and will function as Fosun ...
- Source: drugdu
- 86
- September 21, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.